Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Aranda, A. Carrati, A. Cervantes (1999)
Phase I/II study of escalating doses of weekly irinotecan (CPT-11) in combination with fluorouracil (5-FU) (48h continuous IV infusion) in patients with advanced solid tumors [abstract 1064]Proc Am Soc Clin Oncol, 18
G. Poston, I. Benjamin, T. Diamond, M. Finch-Jones, R. Parks, J. Primrose, M. Rees, DJ Sherlock, S. Yeung, P. Carita, C. Nicholls (2001)
Costs of neoadjuvant chemotherapy and surgery in patients with liver metastases from advanced colorectal cancerJournal of Medical Economics, 4
D. Cunningham, S. Falk, D. Jackson (2000)
Irinotecan and infusional 5-fluorouracil as first line treatment of metastatic colorectal cancer: improved survival and cost-effective compared with infusional 5-FU
C. Nicholls, J. Cassidy, N. Freemantle, M. Harrison, P. Carita (2001)
Cost-effectiveness of combination chemotherapy (oxaliplatin or irinotecan in combination with 5-FU/FA) compared with 5-FU/FA aloneJournal of Medical Economics, 4
P. Piedbois, P. Rougier, M. Buyse, J. Pignon, L. Ryan, R. Hansen, B. Zee, B. Weinerman, J. Pater, C. Leichman, J. Macdonald, J. Benedetti, J. Lokich, J. Fryer, G. Brufman, R. Isacson, A. Laplanche, E. Levy (1998)
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 1
Clare Topham, Judith Moore (1997)
Patient preferences for chemotherapy schedules used in the treatment of advanced colorectal cancer--a pilot study.European journal of cancer care, 6 4
Y. Fong, J. Fortner, Ruth Sun, M. Brennan, L. Blumgart (1999)
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.Annals of surgery, 230 3
E. Cvitkovic, M. Békradda (1999)
Oxaliplatin: a new therapeutic option in colorectal cancer.Seminars in oncology, 26 6
R. Stangl, A. Altendorf-Hofmann, R. Charnley, J. Scheele (1994)
Factors influencing the natural history of colorectal liver metastasesThe Lancet, 343
M. Miwa, M. Ura, Miwa Nishida, N. Sawada, T. Ishikawa, K. Mori, N. Shimma, I. Umeda, H. Ishitsuka (1998)
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.European journal of cancer, 34 8
E. Levy, P. Piedbois, M. Buyse, J. Pignon, P. Rougier, L. Ryan, R. Hansen, B. Zee, B. Weinerman, J. Pater, C. Leichman, J. Macdonald, J. Benedetti, J. Lokich, J. Fryer, G. Brufman, R. Isacson, A. Laplanche, E. Quinaux, P. Thirion (1998)
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 11
M. Vaiani, S. Trippoli, A. Messori (2001)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.The New England journal of medicine, 344 4
M. Peckham, H. Pinedo, U. Veronesi (1996)
Oxford textbook of oncologyBiomedicine & Pharmacotherapy, 2
M. Groener, B. Ineveld, G. Byttebier, B. Hout, F. Rutten (1999)
An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.Anti-cancer drugs, 10 3
J. Scheele (1993)
Hepatectomy for liver metastasesBritish Journal of Surgery, 80
G. Cocconi, D. Cunningham, E. Cutsem (1998)
Open, randomised, multicenter trial of raltitrexed versus fluorouracii plus high-dose leucovorin in patients with advanced colorectal cancerJ Clin Oncol, 16
R. Mayer (1992)
Chemotherapy for metastatic colorectal cancerCancer, 70
C. Nicholls, J. Cassidy, N. Freemantle, M. Harrison, P. Carita (2001)
Cost-effectiveness of oxaliplatin in combination with 5-FU/FA compared with 5-FU/FA aloneJournal of Medical Economics, 4
S. Payne (1992)
A study of quality of life in cancer patients receiving palliative chemotherapy.Social science & medicine, 35 12
R. Pazdur, M. Vincent (1997)
Raltitrexed (Tomudex) versus 5-flourouracil and leucovorin (5-FU + LV in patients with advanced colorectal cancer (ACC): results of a randomised, multi-center, North American trial [abstract 801]Proc Ara Soc Clin Oncol, 16
L.B. Saltz, P.K. Locker, N. Pirotta (1999)
Weekly irinotecan (CPT-11). leucovorin (LV) and fiuorouracil (5-FU) is superior to daily x 5 LV/FU in patients (pts) with previously untreated raetastatic colorectal cancer (CRC) [abstract 898]Proc Am Soc Clin Oncol, 18
G. Blijham (1991)
Chemotherapy of colorectal cancer.Anti-cancer drugs, 2 3
T. Maughan, R. James, D. Kerr, J. Ledermann, C. McArdle, M. Seymour, D. Cohen, Penny Hopwood, C. Johnston, R. Stephens (2002)
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trialThe Lancet, 359
(1995)
Efficacy of adjuvant fluorouracii and folinic acid in colon cancerLancet, 345
M. Borner, P. Schaffski, R. Wit (2000)
A randomised cross-over triai comparing orai LIFT (uracil/tegafur) + leucovorin (LV) and intravenous fluorouracil (FU) + LV for patient preferences and pharmacokinetic studies in advanced colorectal cancer [abstract 741]Proc Am Soc Clin Oncol, 19
Mark DeMario, M. Ratain (1998)
Oral chemotherapy: rationale and future directions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 7
E. Cvitkovic, M. Bekradda (1999)
Oxaliplatin: a new therapeutic option in colorectal cancerSeroin Oncol, 26
V. Gillies-Amar, M.L. Garcia, A. Sebille (1999)
Evolution of severe sensory neuropathy with oxaliplatin, combined to the bimonthly 48h leucovorin (LV) and 5-fluor ouracil (5-FU) regimens (FOLFOX) in metastatic colorectal cancer [abstract 944]Proc Am Soc Clin Oncol, 18
B. Nordlinger, M. Guiguet, J. Vaillant, P. Balladur, K. Boudjema, P. Bachellier, D. Jaeck, Association Chirurgie (1996)
Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patientsCancer, 77
R. Elliot (1996)
An analysis of drug costs for the management of chemotherapy-related side effects in advanced colorectal cancer: a comparison between raltitrexed (“Tomudex”) and 5-fluorouracil plus folinic acidJ Oncol Pharm Pract, 2
M. Sculpher, M.K. Palmer, A. Heyes (2000)
Costs incurred by patients undergoing advanced colorectal cancer therapy: a comparison of raltitrexed and fluorourail plus folinic acidPharmacoeconomics, 17
Brian Ferguson, D. Feeny, G. Guyatt, Peter Tugwell, M. Drummond, G. Stoddart, G. Torrance (1988)
Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care ProgrammesCanadian Public Policy-analyse De Politiques, 14
S. Giacchetti, M. Itzhaki, G. Gruia, R. Adam, R. Zidani, F. Kunstlinger, S. Brienza, E. Alafaci, F. Bertheault-Cvitkovic, C. Jasmin, M. Reynés, H. Bismuth, Misset Jl, F. Lévi (1999)
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.Annals of oncology : official journal of the European Society for Medical Oncology, 10 6
Francis Lévi, R. Zidani, J. Vannetzel, Bruno Perpoint, C. Focan, R. Faggiuolo, P. Chollet, C. Garufi, M. Itzhaki, Luigi Dogliotti, S. Lacobelli, René Adam, Francis Kunstlinger, J. Gastiaburu, Henri Bismuth, Claude Jasmin, J. Misset (1994)
Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.Journal of the National Cancer Institute, 86 21
E. Cutsem, M. Findlay, B. Osterwalder, W. Kocha, D. Dalley, R. Pazdur, J. Cassidy, L. Dirix, C. Twelves, D. Allman, J. Seitz, J. Schölmerich, H. Burger, J. Verweij (2000)
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 6
M.L. Rothenberg, R. Padzur, E.K. Rowinsky (1997)
A phase II multicenter trial of alternating cycles of irinotecan (CPT-11) and 5-FU/leucovorin in patients with previously untreated metastatic colorectal cancer [abstract 944]Proc Am Soc Clin Oncol, 16
R. Midgley, D. Kerr (1999)
Colorectal cancerLancet, 353
L. Saltz, J. Cox, C. Blanke, L. Rosen, L. Fehrenbacher, M. Moore, J. Maroun, S. Ackland, P. Locker, N. Pirotta, G. Elfring, L. Miller (2000)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.The New England journal of medicine, 343 13
B.A. Conley, R.S. Kaplan, S.G. Arbuck (1998)
National Cancer Institute clinical triais program in colorectal cancerCancer Chemother Pharmacol, 42
A. Young, C. Topham, J. Moore, J. Turner, J. Wardle, M. Downes, V. Evans, S. Kay (1999)
A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes.European journal of cancer care, 8 3
Y. Rustum, A. Harstrick, Shousong Cao, U. Vanhoefer, M. Yin, H. Wilke, S. Seeber (1997)
Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 1
Chris Twelves, Michael Boyer, Michael Findlay, J. Cassidy, C. Weitzel, C. Barker, B. Osterwalder, C. Jamieson, K. Hieke (2001)
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.European journal of cancer, 37 5
P. Piedbois (1992)
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 6
H.J. Schmoll, C.H. Kohne, M. Lorenz (2000)
Weekly 24h infusion of high-dose (HD) 5-fluorouracil (5-FU24h) with or without folinic acid (FA) vs. boius 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): a randomised phase III study of the EORTC GITCCG and the AIO [abstract 935]Proc Am Soc Clin Oncol, 19
M. Adson, J. Heerden, M. Adson, James Wagner, D. Ilstrup (1984)
Resection of hepatic metastases from colorectal cancer.Archives of surgery, 119 6
P. Rougier, E. Cutsem, E. Bajetta, N. Niederle, K. Possinger, R. Labianca, M. Navarro, R. Morant, H. Bleiberg, J. Wils, L. Awad, P. Hérait, C. Jacques (1998)
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerThe Lancet, 352
Y. Shimada, M. Yoshino, A. Wakui (1993)
Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer in chemotherapy-naïve patients pretreated with fluorouracil-based chemotherapyJ Clin Oncol, 11
S. Giacchetti, M. Itzhaki, G. Gruia (1999)
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional 5-fluorouracil, leucovorin, oxalipiatin and surgeryAnn Oncol, 10
Jenkins Lt, K. Millikan, S. Bines, Edgar Staren, A. Doolas (1997)
Hepatic resection for metastatic colorectal cancer.The American surgeon, 63 7
P. Rougier, C. Milan, F. Lazorthes, G. Fourtanier, C. Partensky, H. Baumel, J. Faivre (1995)
Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancerBritish Journal of Surgery, 82
T. Ishikawa, F. Sekiguchi, Y. Fukase, N. Sawada, H. Ishitsuka (1998)
Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.Cancer research, 58 4
J. Scheele, Richard Stang, A. Altendorf-Hofmann, M. Paul (2004)
Resection of colorectal liver metastasesWorld Journal of Surgery, 19
P. Rougier, C. Milan, F. Lazorthes (1995)
Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer: Fondation Francaise de Cancerologie DigestiveBr J Surg, 82
Alfred Marshall
Principles of Economics
M.F. Drarnmond, B. O’Brien, G.L. Stoddart (1997)
Methods for the economic evaluation of health care programmes
G. Cocconi, David Cunningham, E. Cutsem, E. François, Bengt Gustavsson, G. Hazel, D. Kerr, Kurt Possinger, S. Hietschold (1998)
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 9
D. Cunningham, J.R. Zalcberg, U. Rath (1996)
Final results of a randomised trial comparing “Tomudex” (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancerAnn Oncol, 7
P. Schlag, Peter Hohenberger, Christian Herfarth (1990)
Resection of liver metastases in colorectal cancer--competitive analysis of treatment results in synchronous versus metachronous metastases.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 16 4
A. Mehrez, A. Gafni (1989)
Quality-adjusted Life Years, Utility Theory, and Healthy-years EquivalentsMedical Decision Making, 9
R.M. Goldberg, R.F. Morton, D.J. Sargent (2002)
N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5-FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC): initial toxicity and response data from a GI Intergroup study [abstract 511]Proc Am Soc Clin Oncol, 21
David Torgerson, Cam Donaldson, D Reid (1994)
Private versus social opportunity cost of time: valuing time in the demand for health care.Health economics, 3 3
C. Punt (1998)
New drugs in the treatment of colorectal carcinomaCancer, 83
K. Chu, R. Tarone, W. Chow, B. Hankey, L. Ries (1994)
Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990.Journal of the National Cancer Institute, 86 13
P. Hoff, R. Ansari, G. Batist, J. Cox, W. Kocha, M. Kuperminc, J. Maroun, D. Walde, C. Weaver, Evelyn Harrison, H. Burger, B. Osterwalder, A. Wong, Ralf Wong (2001)
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 8
A. Gramont, J. Bosset, Chantal Milan, P. Rougier, O. Bouché, P. Etienne, F. Morvan, C. Louvet, T. Guillot, E. François, L. Bedenne (1997)
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 2
G. Bastian, F. Grossin, A. Benharomouda (1998)
A pharmacokinetic study of CPT-11 and 5-FU combination during a phase I trial [abstract 780]Proc Am Soc Clin Oncol, 17
J. Douillard, D. Cunningham, A. Roth, M. Navarro, R. James, P. Karásek, P. Jandík, T. Iveson, J. Carmichael, M. Alakl, G. Gruia, L. Awad, P. Rougier (2000)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialThe Lancet, 355
N. Gunasekara, D. Faulds (1998)
Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.Drugs, 55 3
M. Summerhayes (1996)
Raltitrexed and the treatment of advanced colorectal cancerJournal of Oncology Pharmacy Practice, 2
M. Rees, G. Plant, S. Bygrave (1997)
Late results justify resection for multiple hepatic metastases from colorectal cancerBritish Journal of Surgery, 84
O. Rixe, Waldo Ortuzar, M. Álvarez, R. Parker, E. Reed, K. Paull, T. Fojo (1996)
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.Biochemical pharmacology, 52 12
M. Borner (1999)
Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer--too good to be true?Annals of oncology : official journal of the European Society for Medical Oncology, 10 6
D.M. Parkin, P. Pisani, J. Ferlay (1999)
Global cancer statisticsCA Cancer J Clin, 49
D. Kerr, K. O’Connor (1999)
An economic comparison of the net clinical benefit and treatment costs of raltitrexed and 5-fluorouracil + leucovorin (Mayo regimen) in advanced colorectal cancerJournal of Medical Economics, 2
David Cunningham, John Zalcberg, U. Rath, I. Oliver, E. Cutsem, C. Svensson, J. Seitz, Peter Harper, D. Kerr, G. Pérez-Manga (1996)
Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.Annals of oncology : official journal of the European Society for Medical Oncology, 7 9
R. Labianca, S. Marsoni, G. Pancera, V. Torri, A. Zaniboni, C. Erlichman, J. Pater, L. Shepherd, B. Zee, J. Seitz, C. Milan, J. Pignon (1995)
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigatorsThe Lancet, 345
J. Lokich, J. Ahlgren, J. Gullo, James Philips, J. Fryer (1989)
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 7 4
D. Cunningham, S. Pyrhönen, R. James, C. Punt, T. Hickish, Reino Heikkila, T. Johannesen, H. Starkhammar, C. Topham, L. Awad, C. Jacques, P. Hérait (1998)
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 352
Y. Shimada, M. Yoshino, A. Wakui, I. Nakao, K. Futatsuki, Y. Sakata, M. Kambe, T. Taguchi, N. Ogawa (1993)
Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 5
T. André, M. Bensmaine, C. Louvet, E. François, V. Lucas, F. Desseigne, K. Beerblock, O. Bouché, E. Carola, Y. Merrouche, F. Morvan, G. Dupont-André, A. Gramont (1999)
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 11
W. Scheithauer, H. Rosen, G. Kornek, Christian Sebesta, D. Depisch, Gabriela-Verena Komek (1993)
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.British Medical Journal, 306
Paul Ross, J. Heron, David Cunningham (1996)
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.European journal of cancer, 32A Suppl 5
M. Rothenberg, J. Cox, R. Devore, J. Hainsworth, R. Pazdur, S. Rivkin, J. Macdonald, C. Geyer, J. Sandbach, Daniel Wolf, J. Mohrland, G. Elfring, L. Miller, D. Hoff (1999)
A multicenter, Phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinomaCancer, 85
M. Summerhayes, Steven Wanklyn, R. Shakespeare, J. Lovell (1997)
Reduced pharmacy resource utilization associated with raltitrexed treatment of advanced colorectal cancerJournal of Oncology Pharmacy Practice, 3
Y. Fong, L. Blumgart, J. Fortner, M. Brennan (1995)
Pancreatic or liver resection for malignancy is safe and effective for the elderly.Annals of Surgery, 222
R. Pazdur, J.-Y. Douillard, J.R. Skiliings (1999)
Multicenter phase III study of 5-fluorouracil (5-FU) of LIFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer [abstract 1009]Prix Ara Soc Clin Oncol, 18
Sarah Landis, Taylor Murray, Sherry Bolden, P. Wingo (1999)
Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 49
K. Hughes, R. Simon, S. Songhorabodi, M. Adson, D. Ilstrup, J. Fortner, B. Maclean, J. Foster, J. Daly, D. Fitzherbert (1986)
Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence.Surgery, 100 2
S. Trippoli, M. Vaiani, F. Cattel, A. Messori (2000)
Cost-effectiveness of irinotecan in advanced colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 11 7
M. Ducreux, M. Ychou, Jean-François Seitz, M. Bonnay, Alice Bexon, J. Armand, M. Mahjoubi, D. Mery-mignard, P. Rougier (1999)
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 9
R. Elliott (1996)
An analysis of drug costs for the management of chemotherapy-related side effects in advanced colorectal cancerJournal of Oncology Pharmacy Practice, 2
R. Doci, L. Gennari, P. Bignami, F. Montalto, A. Morabito, F. Bozzetti (1991)
One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinantsBritish Journal of Surgery, 78
David Cunningham, Stephen Falk, Daniel Jackson (2002)
Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancerBritish Journal of Cancer, 86
E. Cutsem, C. Twelves, J. Cassidy (2001)
Oral capecitabine with metastatic colorectal cancer: results of a large phase II studyJ Clin Oncol, 19
J. Scheele, R. Stangl, A. Altendorf-Hofmann (1990)
Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural historyBritish Journal of Surgery, 77
D. Cunningham (1998)
Mature results from three large controlled studies with raltitrexed ('Tomudex').British Journal of Cancer, 77
Al Benson (1998)
Therapy for advanced colorectal cancer.Seminars in oncology, 25 5 Suppl 11
P. Wingo, Lynn Ries, S. Parker, C. Heath (1998)
Long-term cancer patient survival in the United States.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 7 4
M. Caudry, C. Bonnel, A. Floquet, C. Marsault, P. Quetin, J. Pujol, Olivier Maton, J. Dujols, Y. Caudry, P. Skawinski, J. Carenco, F. Mokhtari, D. Célérier, A. Quinton, H. Demeaux, J. Maire (1995)
A Randomized Study of Bolus Fluorouracil Plus Folinic Acid Versus 21‐Day Fluorouracil Infusion Alone or in Association with Cyclophosphamide and Mitomycin C in Advanced Colorectal CarcinomaAmerican Journal of Clinical Oncology, 18
R. Jamison, J. Donohue, D. Nagorney, C. Rosen, W. Harmsen, D. Ilstrup (1997)
Hepatic resection for metastatic colorectal cancer results in cure for some patients.Archives of surgery, 132 5
E. Cutsem, C. Pozzo, H. Starkhammar, L. Dirix, E. Terzoli, F. Cognetti, Y. Humblet, C. Garufi, L. Filez, G. Gruia, C. Cote, C. Barone (1998)
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 9 11
Geoffrey Liu, E. Franssen, M. Fitch, E. Warner (1997)
Patient preferences for oral versus intravenous palliative chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 1
E. Cutsem, C. Twelves, J. Cassidy, D. Allman, E. Bajetta, M. Boyer, R. Bugat, M. Findlay, S. Frings, Michaela Jahn, J. Mckendrick, B. Osterwalder, G. Pérez-Manga, R. Rosso, P. Rougier, W. Schmiegel, J. Seitz, P. Thompson, J. Viéitez, C. Weitzel, P. Harper (2001)
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 21
J. Sastre, L. Paz-Ares, E. Díaz-Rubio, H. Cortés-Funes, A. Carcas, G. Gruia, P. Hérait, C. Chacon, C. Martín, I. Farr (1997)
Phase I dose finding study of irinotecan (CPT-11) over a short i.v. infusion combined with a fixed dose of 5-fluorouracil (5-FU) protracted continuous i.v. infusion in patients with advanced solid tumoursEuropean Journal of Cancer, 33
W.T. Huinink, V. Moiseyenko, B. Glimelius (2000)
A randomised phase II multicenter trial of irinotecan (CPT-11) using different schedules in patients with metastatic colorectal cancer (MCRC) [abstract 951]Proc Am Soc Ciin Oncol, 17
M. Forni, R. Bugat, G. Chabot, S. Culine, J. Extra, A. Gouyette, I. Madelaine, Michel Marty, A. Mathieu-Boué (1994)
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.Cancer research, 54 16
M. Forni, R. Bugrat, C.G. Chabot (1994)
Phase I and pharmacokinetic study of the camptathecin derivative irinotecan, administered on a weekly schedule in colorectal cancerCancer Res, 54
K. Chu, R. Tarone, W. Chow (1994)
TEMPORAL PATTERN IN COLORECTAL CANCER INCIDENCE, SURVIVAL AND MORTALITY, 86
A. Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortés-Funes, A. Cervantes, G. Freyer, D. Papamichael, N. Bail, C. Louvet, D. Hendler, F. Braud, C. Wilson, F. Morvan, A. Bonetti (2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 16
C. Leichman, T. Fleming, F. Muggia, C. Tangen, B. Ardalan, J. Doroshow, F. Meyers, R. Holcombe, G. Weiss, A. Mangalik (1995)
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 6
T. Gayowski, S. Iwatsuki, Juan, Madariaga, R. Selby, S. Todo, W. Irish, T. Starzl (1994)
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors.Surgery, 116 4
(1992)
Modulation of flurouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rateJ Clin Oncol, 10
T. André, C. Louvet, F. Maindrault-Goebel, C. Couteau, M. Mabro, J. Lotz, V. Gilles-Amar, M. Krulik, E. Carola, V. Izrael, A. Gramont (1999)
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.European journal of cancer, 35 9
C. Tournigand, E. Achille, G. Lledo (2000)
FQLFIRI followed by FOLFOX or FOLFOX followed by FOLFIRI in raetastatic colorectal cancer (MCRC): preliminary results of a randomised phase III study of the GERCOR [abstract]Ann Oncol, 11
D. Khayat, M. Gil-delgado, É. Antoine, D. Nizri, G. Bastian (2001)
The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.Oncology, 15 4
T.S. Maughan, R.D. James, D. Kerr (2002)
A multicentre randomised trial comparing survival, palliation and quality of life for 3 chemotherapy regimens (de Gramont, Lokich and raltitrexed) in metastatic colorectal cancerLancet, 359
C. Lévy-Piedbois, Isabelle Durand-Zaleski, H. Juhel, C. Schmitt, A. Bellanger, Pascal Piedbois (2000)
Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 11 2
J. Ledermann, T. Maughan, R. James, D. Kerr, C. McArdle, M. Seymour, C. Johnston, R. Stephens (1999)
Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (De Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer.British Journal of Cancer
J. Hale, D. Cohen, T. Maughan, R. Stephens (2002)
Costs and consequences of different chemotherapy regimens in metastatic colorectal cancerBritish Journal of Cancer, 86
S. Giacchetti, B. Perpoint, R. Zidani, N. Bail, R. Faggiuolo, C. Focan, P. Chollet, J. Llory, Y. Létourneau, B. Coudert, F. Bertheaut-Cvitkovic, D. Larregain-Fournier, A. Rol, S. Walter, R. Adam, J. Misset, F. Lévi (2000)
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 1
D. Lister-Sharp, MS McDonagh, K. Khan, J. Kleijnen, M. Irving, Sheila Adam, Angela Coulter, Anthony Culyer, John Farndon, Michael Maisey, Michael Rawlins, Richard Lilford, J. Tripp, J. Woodin (2000)
A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.Health technology assessment, 4 17
Willard Manning (1987)
Health insurance and the demand for medical care: evidence from a randomized experiment.The American economic review, 77 3
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.The New England journal of medicine, 350 23
F. Lévi, R. Zidani, J. Misset (1997)
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancerThe Lancet, 350
R. Or, Yosef Kupaluchnik, P. Drakos, A. Nagler, Y. Cass (1997)
A comparison of the safety and efficacy of ondansetron versus granisetron as prophylaxis against chemo/ radiotherapy-induced nausea and vomiting in bone marrow transplantation patients. A double-blinded, randomized, prospective, pilot studyJournal of Oncology Pharmacy Practice, 3
A. Benhammouda, G. Bastian, O. Rixe (1997)
A phase I and pharmacokinetic (PK) study of CPT-11 (C) and 5-FU (F) combination [abstract 710]Proc Am Soc Clin Oncol, 16
A. Jungwirth, J. Pinski, Georg Galvan, G. Halmos, K. Szepesházi, R. Gai, K. Groot, M. Vadillo-Buenfil, A. Schally (1997)
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.European journal of cancer, 33 7
IIan Ron, A. Lotan, M. Inbar, S. Chaitchik (1996)
Advanced colorectal carcinoma: redefining the role of oral ftorafurAnti-Cancer Drugs, 7
After many years of fluorouracil being a standard part of various treatment regimens for patients with advanced or metastatic colorectal cancer, new agents are now available. The purchase costs of these novel agents are higher than for fluorouracil, so the question is whether these options are cost-effective. This review focuses on cost-effectiveness, concentrating mainly on the drug costs that constitute only a small percentage of the overall cost of cancer care, but are a major focus in the planning of healthcare services.
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.